Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 125 clinical trials
Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD (RECUT)

Background Chronic obstructive pulmonary disease (COPD) is a major public health issue with no curative treatment. In Switzerland estimated 5-7% of the total population are suffering from this chronic disease. According to current guidelines corticosteroids are part of treatment of acute exacerbations in COPD patients. Several studies suggest that corticosteroids …

prednisone
forced expiratory volume
dyspnea
obstruction
bronchiectasis
  • 17 views
  • 22 Jan, 2022
  • 1 location
Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

The primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator cuff disease. The study will enroll 65 patients, aged 40-75 years old, in a longitudinal case series level IV study using extended release triamcinolone to …

rotator cuff syndrome
triamcinolone
fx006
NSAID
nonsteroidal anti-inflammatory drugs
  • 0 views
  • 02 Dec, 2021
  • 1 location
Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study

Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids

  • 0 views
  • 26 Dec, 2021
  • 1 location
A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19. (LEONARDO)

in a 2:1 ratio to receive either Plerixafor (n=100) or placebo (n=50) as a continuous IV infusion for 7 days (from D1 to D8) in addition to standard of care (e.g. glucocorticoids...).

  • 0 views
  • 15 Oct, 2022
  • 8 locations
Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response - A Randomized Double-blind Placebo-controlled Trial

The aim of the study is to compare the effect of a repeat moderate dose of glucocorticoids postoperatively after preoperative high dose upon postoperative pain after Total Knee Arthroplasty (TKA

  • 0 views
  • 23 Oct, 2022
  • 1 location
Efficacy of Fecal Microbial Transplantation Treatment in Adults With Atopic Dermatitis

each 2 weeks apart. Patients will be allowed to continue with their baseline medical topical treatment, including moisturizers and glucocorticoids, during the study period, but no new therapy should be

corticosteroids
topical corticosteroid
atopy
topical agents
  • 32 views
  • 04 Oct, 2022
  • 2 locations
Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage (FINISHER)

contributes to DCI and therefore poor outcome and plays a major role in SAH. Some studies suggest a beneficial effect of anti-inflammatory drugs like glucocorticoids (GC) in SAH patient, but there are no

  • 0 views
  • 03 Jun, 2022
  • 7 locations
The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients. (Dexa)

Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. Recovery time after thyroid surgery may depend on several factors, such as

postoperative nausea
drainage
postoperative vomiting
vomiting
calcium
  • 0 views
  • 24 Mar, 2022
  • 1 location
Dexamethasone and Robotic-assisted Hysterectomy

minimize surgical stress. Glucocorticoids provide significant analgesic and antiemetic effects but its role in a fast-track, multi-modal setting is not settled when discharge is planned within 24-36 hours

  • 0 views
  • 04 Oct, 2022
  • 1 location
Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease

diagnosed, glucocorticoids with or without calcineurin inhibitor (CNI) are first-line drugs, but the effective rate is less than 50%, and the prognosis of hormone-resistant severe cGVHD is extremely poor

  • 0 views
  • 15 Dec, 2021
  • 1 location